News
ESPR
2.170
+5.85%
0.120
Esperion Therapeutics: Reinforced Buy Rating on Strengthened Investment Story and Conference-Driven Upside Catalysts
TipRanks · 1d ago
Weekly Report: what happened at ESPR last week (0406-0410)?
Weekly Report · 2d ago
Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound?
NASDAQ · 6d ago
Analysts Offer Insights on Healthcare Companies: Esperion (ESPR), PROCEPT BioRobotics (PRCT) and Vericel (VCEL)
TipRanks · 04/06 11:00
Weekly Report: what happened at ESPR last week (0330-0403)?
Weekly Report · 04/06 09:20
Esperion Completes Corstasis Acquisition, Expands Cardiovascular Portfolio
TipRanks · 04/02 21:33
ESPERION THERAPEUTICS INC - INCURS $25 MLN IN ADDITIONAL TERM LOANS ON APRIL 2, 2026 - SEC FILING
Reuters · 04/02 20:29
Esperion, Athyrium Capital enter $50M royalty financing agreement
TipRanks · 04/02 20:16
Esperion enters $50 million Japan royalty financing with Athyrium Capital Management
Reuters · 04/02 20:08
ESPERION THERAPEUTICS INC - ATHYRIUM FUNDS TO BUY 100% OF ESPERION'S ROYALTY INTEREST ON OTSUKA'S JAPAN SALES FROM JAN 1, 2026
Reuters · 04/02 20:05
Esperion closes acquisition of Corstasis, adds Enbumyst nasal spray diuretic
Reuters · 04/02 20:00
*Esperion Therapeutics Closes Acquisition Of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise With Enbumyst(TM) (bumetanide Nasal Spray) >ESPR
Dow Jones · 04/02 20:00
Esperion Therapeutics Earnings Call Signals Expansion
TipRanks · 04/02 00:05
Esperion to present at Needham Virtual Healthcare Conference webcast
Reuters · 03/31 21:52
Esperion Therapeutics: CLEAR Outcomes Stroke Data and Commercial Momentum Underscore Buy-Rated Cardiovascular Franchise
TipRanks · 03/31 10:38
Analysts Have Conflicting Sentiments on These Healthcare Companies: Passage Bio (PASG), Phreesia (PHR) and Esperion (ESPR)
TipRanks · 03/31 08:50
Merck oral PCSK9 enlicitide shows improved cholesterol lowering vs. non-statins
Seeking Alpha · 03/30 18:54
Esperion showcases new data from CLEAR Outcomes trial
TipRanks · 03/30 13:21
Esperion says CLEAR Outcomes analysis shows Nexletol cuts ischemic stroke risk 22%
Reuters · 03/30 12:05
Esperion (ESPR) Gets a Buy from Piper Sandler
TipRanks · 03/30 11:27
More
Webull provides a variety of real-time ESPR stock news. You can receive the latest news about Esperion Therape through multiple platforms. This information may help you make smarter investment decisions.
About ESPR
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (CVD) and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines to lower the risk of myocardial infarction and coronary revascularization in adults with primary hyperlipidemia. Its NEXLETOL is an ATP Citrate Lyase (ACLY), inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.